S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
NASDAQ:IOVA

Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

$4.48
+0.04 (+0.90%)
(As of 01:57 PM ET)
Compare
Today's Range
$4.38
▼
$4.57
50-Day Range
$4.44
▼
$7.80
52-Week Range
$4.38
▼
$10.41
Volume
2.26 million shs
Average Volume
5.21 million shs
Market Capitalization
$1.11 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.54
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Iovance Biotherapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.77 Rating Score
Upside/​Downside
344.1% Upside
$19.54 Price Target
Short Interest
Bearish
15.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.49
Upright™ Environmental Score
News Sentiment
0.81mentions of Iovance Biotherapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$26.56 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.87) to ($1.41) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.70 out of 5 stars

Medical Sector

88th out of 963 stocks

Biological Products, Except Diagnostic Industry

10th out of 159 stocks

See Top Rated MarketRank™ Stocks Here

IOVA stock logo

About Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

IOVA Price History

IOVA Stock News Headlines

September 25, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), DENTSPLY SIRONA (XRAY) and Apellis Pharmaceuticals (APLS)
September 22, 2023 | benzinga.com
Iovance Biotherapeutics Director Makes $55K Stock Purchase
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 20, 2023 | americanbankingnews.com
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Short Interest Update
September 20, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 4.9% Following Analyst Downgrade
September 19, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Lowered to $18.00 at Barclays
September 19, 2023 | americanbankingnews.com
Iovance Biotherapeutics Sees Unusually High Options Volume (NASDAQ:IOVA)
September 19, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Sees Unusually-High Trading Volume After Insider Buying Activity
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
September 18, 2023 | seekingalpha.com
Iovance Biotherapeutics: Navigates Regulatory Delays With Strategic Finesse (Rating Upgrade)
September 18, 2023 | msn.com
Barclays Maintains Iovance Biotherapeutics (IOVA) Overweight Recommendation
September 18, 2023 | benzinga.com
Thinking about buying stock in Navios Maritime Holdings, Biodexa Pharmaceuticals, Iovance Biotherapeutics, Neubase Therapeutics, or Iris Energy?
September 18, 2023 | msn.com
PayPal and Dropbox stocks fall after downgrades, GM shares inch higher, and more stocks on the move
September 18, 2023 | benzinga.com
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session
September 18, 2023 | finance.yahoo.com
Independent Director of Iovance Biotherapeutics Wayne Rothbaum Buys 28% More Shares
September 17, 2023 | americanbankingnews.com
Iovance Biotherapeutics' (IOVA) "Buy" Rating Reiterated at Mizuho
September 17, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Earns "Buy" Rating from Truist Financial
September 17, 2023 | americanbankingnews.com
Wayne P. Rothbaum Buys 5,000,000 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Stock
September 17, 2023 | americanbankingnews.com
Iovance Biotherapeutics' (IOVA) Buy Rating Reaffirmed at HC Wainwright
September 17, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Receives Market Outperform Rating from JMP Securities
September 17, 2023 | americanbankingnews.com
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Up on Insider Buying Activity
September 16, 2023 | msn.com
Biggest stock movers today: Arm Holdings and Iovance Biotherapeutics and more
September 16, 2023 | msn.com
Biggest stock movers today: Arm Holdings and Iovance Biotherapeutics
September 15, 2023 | markets.businessinsider.com
Personalized Skin Cancer Therapy, Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics Therapy
September 15, 2023 | markets.businessinsider.com
Iovance Biotherapeutics: FDA Extends PDUFA Date For Iovance BLA On Resource Constraints
September 15, 2023 | marketwatch.com
Iovance Biotherapeutics Shares Rise 11% After FDA Agrees to Expedite Review
September 15, 2023 | msn.com
Iova stock jumps 15% in wake of FDA update on drug lifileucel
See More Headlines
Receive IOVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

IOVA Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IOVA
CUSIP
N/A
CIK
1425205
Web
www.iovance.com
Phone
(650) 260-7120
Fax
N/A
Employees
503
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$19.54
High Stock Price Forecast
$38.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+344.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.77
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-395,890,000.00
Net Margins
N/A
Pretax Margin
-176,181.52%
Return on Equity
-78.33%
Return on Assets
-60.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.10
Quick Ratio
2.99

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.66 per share
Price / Book
1.65

Miscellaneous

Outstanding Shares
247,780,000
Free Float
222,008,000
Market Cap
$1.09 billion
Optionable
Optionable
Beta
0.10

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Frederick G. Vogt Esq. (Age 49)
    J.D., Ph.D., Interim CEO, Pres, Gen. Counsel & Corp. Sec.
    Comp: $1.39M
  • Mr. Jean-Marc Bellemin M.B.A. (Age 50)
    CFO, Principal Accounting Officer & Treasurer
    Comp: $932.2k
  • Dr. Igor P. Bilinsky (Age 50)
    Chief Operating Officer
    Comp: $932.2k
  • Dr. Friedrich Graf Finckenstein M.D. (Age 56)
    Chief Medical Officer
    Comp: $1.06M
  • Ms. Sara Pellegrino
    VP of Investor Relations & PR
  • Ms. Tracy Winton
    Sr. VP of HR
  • Mr. Howard B. Johnson M.B.A. (Age 63)
    Chief Bus. Officer
  • Mr. James Ziegler M.B.A.
    Exec. VP of Commercial
  • Dr. Raj K. Puri M.D.
    Ph.D., Exec. VP of Regulatory Strategy & Translational Medicine
  • Mr. Brian Shew M.B.A.
    Sr. VP & Head of Digital and Information Technology

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IOVA Stock - Frequently Asked Questions

Should I buy or sell Iovance Biotherapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.

What is Iovance Biotherapeutics' stock price forecast for 2023?

13 brokers have issued 1 year target prices for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they expect the company's share price to reach $19.54 in the next year. This suggests a possible upside of 344.1% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.

How have IOVA shares performed in 2023?

Iovance Biotherapeutics' stock was trading at $6.39 at the beginning of the year. Since then, IOVA stock has decreased by 31.1% and is now trading at $4.40.
View the best growth stocks for 2023 here.

When is Iovance Biotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IOVA earnings forecast.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) posted its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.34. The biotechnology company earned $0.24 million during the quarter, compared to the consensus estimate of $3.91 million. During the same quarter in the previous year, the firm earned ($0.63) earnings per share.

What ETFs hold Iovance Biotherapeutics' stock?

ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).ARK Genomic Revolution ETF (ARKG).

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.86%), Perceptive Advisors LLC (5.66%), State Street Corp (5.47%), Point72 Asset Management L.P. (3.14%), Artisan Partners Limited Partnership (1.79%) and Geode Capital Management LLC (1.67%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $4.40.

How much money does Iovance Biotherapeutics make?

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.09 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Iovance Biotherapeutics have?

The company employs 503 workers across the globe.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.

This page (NASDAQ:IOVA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -